COPENHAGEN, DENMARK — Danish pharmaceutical giant Novo Nordisk has confirmed a significant cyberattack involving unauthorized access to internal IT systems, resulting in the exposure of patient data and the external copying of clinical trial information industrialcyber.co . Imagine a vault containing years of sensitive medical research and patient records being quietly accessed and copied—this is exactly what happened at one of the world's most valuable pharmaceutical companies.

The breach involves both personal patient data and non-public information related to the company's AI assets and clinical trials cyberpress.org . While Novo Nordisk has not disclosed the exact number of affected individuals, the scope is significant given the company's global operations in diabetes care and obesity treatments. Notably, no threat actor has publicly claimed responsibility for the attack yet securityaffairs.com .

The hack-and-leak group FulcrumSec claims to have stolen 1.3TB of data from Novo Nordisk, though the company has not confirmed this specific figure or attributed the attack to any particular group www.securityweek.com .

This incident highlights the growing threat to pharmaceutical infrastructure, where attackers target not just financial data but also valuable intellectual property and sensitive health information. The company has launched an investigation with cybersecurity experts and is working with law enforcement. Patients and trial participants are being notified, and the company is offering identity protection services to those affected.